

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM816139

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Sun Pharmaceuticals Industries, Inc.		05/09/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	MiCal Pharmaceuticals LLC		
Street Address:	9025 Balboa Avenue, Suite 115		
City:	San Diego		
State/Country:	CALIFORNIA		
Postal Code:	92123		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1647847	ULTRAVATE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(858) 800-2537		
Email:	jonathan@ns-lg.com		
Correspondent Name:	Jonathan A. Muenkel		
Address Line 1:	1106 Second Street, #831		
Address Line 4:	Encinitas, CALIFORNIA 92024		
ATTORNEY DOCKET NUMBER:	102-00003		
NAME OF SUBMITTER:	Jonathan A. Muenkel		
SIGNATURE:	/Jonathan A. Muenkel/		
DATE SIGNED:	06/06/2023		
Total Attachments: 3			
source=20230606_102-00003-1647847_assignment#page1.tif			
source=20230606_102-00003-1647847_assignment#page2.tif			
source=20230606_102-00003-1647847_assignment#page3.tif			

OP \$40.00 1647847

Trademark Assignment

This **TRADEMARK ASSIGNMENT** (the "Assignment") is effective as of April 14, 2023, and is made from **Sun Pharmaceuticals Industries, Inc.**, a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 2 Independence Way, Princeton, NJ 08540 ("Assignor") on the one hand, to **MiCal Pharmaceuticals LLC – H Series**, with its principal place of business at 9025 Balboa Avenue, Suite 115, San Diego, CA 92123 ("Assignee") on the other hand.

WHEREAS, Assignor owns the mark set forth in the attached Schedule I (the "Mark");
and

WHEREAS, Ranbaxy Laboratories, Inc., as acquired by Sun Pharmaceutical Industries Ltd., Assignor's parent company, and Assignee have agreed to terminate a Collaboration and License Agreement, dated effective March 13, 2013, and whereby, Assignee wishes to acquire from Assignor, and Assignor wishes to transfer to Assignee, the Mark and the goodwill associated with the Mark;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor.

1. Assignment. Assignor hereby conveys, assigns, transfers, and delivers to Assignee, its successors, and assigns all rights, title, and interests in and to the Mark, the goodwill of the business symbolized by the Mark, all registrations and applications for registration thereof, if any, all rights of action accrued and to accrue under and by virtue thereof, including the right to sue and recover for infringement of said Mark.

2. Further Actions. Assignor agrees to take such further action, execute such additional documents, provide good faith testimony, and, in general, provide all lawful cooperation reasonably requested of it by Assignee, at Assignee's expense, to perfect Assignee's title in and to the Mark and to carry out and fulfill the purposes and intent of this Assignment.


3. Recordation. Assignor hereby requests the U.S. Commissioner of Patents and Trademarks to record this Assignment to Assignee.

4. Miscellaneous. This Assignment will be governed by and construed in accordance with the domestic substantive laws of the State of New York, without regard to its conflict of law principles. The failure of either party to enforce any terms or provisions of this Assignment will not waive any rights under such terms and provisions. This Assignment may be executed in counterparts, each of which will be an original and all of which when taken together will constitute one and the same agreement.


[Signature page follows]

IN WITNESS WHEREOF, the undersigned has caused this Assignment to be executed as of the day and year first written above.

ASSIGNOR:
Sun Pharmaceuticals Industries, Inc.

DocuSigned by:

By: _____
Name: Craig Kuchii
Title: Associate Vice President, Intellectual Property
Date: 5/1/2023

ASSIGNEE:
MiCal Pharmaceuticals LLC – H Series

DocuSigned by:

By: _____
Name: Dan Piacquadio
Title: Manager
Date: 5/9/2023

Schedule I

Trademark

Trademark Registration No.	Mark	Registration Date
U.S. Reg. No. 1,647,847	ULTRAVATE	June 18, 1991